Press Releases OssDsign AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:29:33 2024-05-17 am EDT			5-day change	1st Jan Change
8.88 ^SEK	-4.52%		-10.75%	+11.00%

May. 14	Transcript : OssDsign AB, Q1 2024 Earnings Call, May 14, 2024
May. 14	OssDsign AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Change of financial calendar	May. 16	AQ
OssDsign Q1 - An accelerating turnaround	May. 15	AQ
OssDsign: A new beginning – Q1 review	May. 15	AQ
OssDsign AB (publ) publishes Q1 2024 interim report	May. 14	AQ
OssDsign expands military access with new contract covering 100 additional VA orthopedic hospitals	Apr. 29	AQ
OssDsign: Another quarter of triple-digit Catalyst growth expected	Apr. 11	AQ
OssDsign awarded long-term agreement with Premier, Inc.	Apr. 02	AQ
OssDsign: Update after HC seminar and news in the spinal fusion market	Mar. 07	AQ
OssDsign appoints Tom Buckland as Chief Technical Officer	Feb. 29	AQ
OssDsign: Restructuring completed, focus on 2024	Feb. 07	AQ
OssDsign AB (publ) publishes year-end report 2023	Feb. 06	AQ
OssDsign: Right time to fuse the spine	Jan. 29	AQ
12-month data from the clinical study of OssDsign Catalyst™ published in Biomedical Journal of Scientific & Technical Research	Jan. 24	AQ
OssDsign reports exceptional data from the clinical study TOP FUSION	Jan. 09	AQ
OssDsign - Higher-than-expected Q4 preliminary sales	Dec. 07	AQ
OssDsign's revenues for the fourth quarter of 2023 are expected to exceed market estimates	Dec. 06	AQ
SEB Venture Capital has sold its holding in OssDsign	Nov. 30	AQ
OssDsign changes Certified Adviser to Carnegie Investment Bank AB (publ)	Nov. 30	AQ
OssDsign Q3 - Catalyst is growing as expected	Nov. 22	AQ
OssDsign AB (publ) publishes Q3 2023 Interim Report	Nov. 21	AQ

No results for this search